Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Akebia Therapeutics to post earnings of ($0.07) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). The firm had revenue of $32.61 million during the quarter, compared to the consensus estimate of $41.13 million. During the same quarter in the previous year, the firm posted ($0.14) EPS. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Akebia Therapeutics Stock Performance
Akebia Therapeutics stock traded up $0.05 during mid-day trading on Tuesday, reaching $1.23. The company’s stock had a trading volume of 915,055 shares, compared to its average volume of 3,717,157. The company has a market capitalization of $257.81 million, a price-to-earnings ratio of -5.15 and a beta of 0.77. The business’s 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.38. Akebia Therapeutics has a 12 month low of $0.78 and a 12 month high of $2.48.
Wall Street Analyst Weigh In
View Our Latest Report on AKBA
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Read More
- Five stocks we like better than Akebia Therapeutics
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Learn Technical Analysis Skills to Master the Stock Market
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- How to Invest in Insurance Companies: A Guide
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
